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A B S T R A C T
Background
Inflammation and oedema of the facial nerve are implicated in causing Bell’s palsy. Corticosteroids have a potent anti-inflammatory
action that should minimise nerve damage. This is an update of a review first published in 2002 and last updated in 2010.
Objectives
To determine the effectiveness and safety of corticosteroid therapy in people with Bell’s palsy.
Search methods
On 4 March 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE and LILACS. We reviewed the bibliographies of the randomised trials and contacted known
experts in the field to identify additional published or unpublished trials. We also searched clinical trials registries for ongoing trials.
Selection criteria
Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or
adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the
same therapy was given in a similar way to the experimental group.
Data collection and analysis
We used standard Cochrane methodology. The main outcome of interest was incomplete recovery of facial motor function (i.e. residual
facial weakness). Secondary outcomes were cosmetically disabling persistent sequelae, development of motor synkinesis or autonomic
dysfunction (i.e. hemifacial spasm, crocodile tears) and adverse effects of corticosteroid therapy manifested during follow-up.
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Main results
We identified seven trials, with 895 evaluable participants for this review. All provided data suitable for the primary outcome meta-
analysis. One of the trials was new since the last version of this Cochrane systematic review. Risk of bias in the older, smaller studies
included some unclear- or high-risk assessments, whereas we deemed the larger studies at low risk of bias. Overall, 79/452 (17%)
participants allocated to corticosteroids had incomplete recovery of facial motor function six months or more after randomisation;
significantly fewer than the 125/447 (28%) in the control group (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.50 to 0.80, seven
trials, n = 895). The number of people who need to be treated with corticosteroids to avoid one incomplete recovery was 10 (95% CI
6 to 20). The reduction in the proportion of participants with cosmetically disabling sequelae six months after randomisation was very
similar in the corticosteroid and placebo groups (RR 0.96, 95% CI 0.40 to 2.29, two trials, n = 75, low-quality evidence). However,
there was a significant reduction in motor synkinesis during follow-up in participants receiving corticosteroids (RR 0.64, 95% CI 0.45
to 0.91, three trials, n = 485, moderate-quality evidence). Three studies explicitly recorded the absence of adverse effects attributable to
corticosteroids. One trial reported that three participants receiving prednisolone had temporary sleep disturbances and two trials gave
a detailed account of adverse effects occurring in 93 participants, all non-serious; the combined analysis of data from these three trials
found no significant difference in adverse effect rates between people receiving corticosteroids and people receiving placebo (RR 1.04,
95% CI 0.71 to 1.51, n = 715).
Authors’ conclusions
The available moderate- to high-quality evidence from randomised controlled trials showed significant benefit from treating Bell’s palsy
with corticosteroids.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroids for Bell’s palsy
Review question
What are the effects of corticosteroids on Bell’s palsy?
Background
Bell’s palsy is a paralysis or weakness of muscles in the face, usually on one side, with no certain cause. Symptoms usually recover,
although not always. Reducing inflammation of the facial nerve using corticosteroid medicines (steroids) is thought to limit nerve
damage. This is an update of a review first published in 2002 and last updated in 2010.
Study characteristics
We identified seven clinical trials involving 895 people with one-sided mild, moderate or severe Bell’s palsy of unknown cause. All of
these trials reported rates of incomplete recovery (the proportion of people left with facial weakness) and we were able to combine the
results. People in the studies were aged from 2 to 84 years. They were treated with corticosteroids or placebo (inactive treatment), either
alone or in combination with other therapies. One trial only involved children, from 24 months to 74 months old. The duration of
the included studies for adults and children ranged from 157 days to 12 months.
Key results and quality of the evidence
Incomplete recovery
According to moderate quality to high quality evidence, corticosteroids reduced the number of people left with facial weakness after
Bell’s palsy compared to placebo (a pretend medicine). This finding was based on data from seven studies involving 895 participants
with Bell’s palsy of varying degrees of severity. We calculated that to stop one person from being left with facial weakness, 10 people
need to be treated.
Five studies provided data on long-term after-effects of Bell’s palsy following treatment. Two of the studies (75 participants) looked at
persistent effects on facial appearance after six months or more. The effect was nearly the same for corticosteroids and placebo, showing
that participants who had corticosteroids benefited slightly, although this evidence was low quality. Data from three studies (485
participants) showed clearly that people who received corticosteroids developed less motor synkinesis (unwanted facial movements)
and crocodile tears (watery eyes when eating or chewing), compared with people who received placebo alone. This finding was based
on moderate-quality evidence.
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Side effects
Three studies reported that no side effects could be attributed to corticosteroid treatment. Based on moderate-quality evidence from
three studies (715 participants), numbers experiencing side effects were similar with corticosteroids and placebo.
The evidence is current to March 2016.
3Corticosteroids for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Corticosteroids compared to placebo or no treatment for Bell’s palsy
Patient or population: people with Bell’s palsy
Settings: primary and secondary care
Intervention: cort icosteroids
Comparison: placebo or no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no treat-
ment
Corticosteroids
Incomplete recovery ≥
6 months after ran-
domisation
House-Brack-
mann grading system
and Sunnybrook scale
Follow-up: 157 days to
12 months
281 per 1000 177 per 1000
(140 to 225)
RR 0.63
(0.50 to 0.80)
895
(7 studies)
⊕⊕⊕⊕
high1
NNTB 10,
95% CI 6 to 20
Cosmetically disabling
persistent sequelae ≥
6 months after ran-
domisation
Clinical assessment
Follow-up: mean 6
months
216 per 1000 208 per 1000
(86 to 495)
RR 0.96
(0.4 to 2.29)
75
(2 studies)
⊕⊕©©
low2,3
-
M otor synkinesis and
crocodile tears
Clinical assessment
Follow-up: 9 to 12
260 per 1000 167 per 1000
(117 to 237)
RR 0.64
(0.45 to 0.91)
485
(3 studies)
⊕⊕⊕©
moderate4
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Adverse effects
Follow-up: 9 to 12
months
127 per 1000 133 per 1000
(91 to 192)
RR 1.04
(0.71 to 1.51)
715
(3 studies)
⊕⊕⊕©
moderate5
3
other studies recorded
that no adverse ef fects
occurred with cort icos-
teroid treatment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Two trials excluded part icipants who were found to have clinical evidence of herpes zoster infect ion (Lagalla 2002; Taverner
1954). In addit ion, two studies did not use a scoring system such as the House-Brackmann or Sunnybrook scale to assess
facial motor funct ion, relying upon clinical examinat ion, electromyographic tests or photographs (May 1976; Taverner
1954). Taverner 1954 reported outcomes at f ive months rather than at six months or more. However, we felt that these
lim itat ions did not compromise the generalisability of the f indings.
2 We downgraded twice: f irst for imprecision - there was a low number of events and pooled RR allowed the possibility of both
no ef fect and the chance of harm; second for publicat ion bias - of the seven included studies, f ive did not provide data on the
presence of cosmetically disabling sequelae six months or more af ter randomisat ion.
3 We downgraded once for imprecision. There was a low number of events.
4 We downgraded the quality of the evidence to moderate because of publicat ion bias.
5 We downgraded for publicat ion bias - only three of seven studies provided data on adverse ef fects.
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B A C K G R O U N D
Description of the condition
Bell’s palsy is an acute, generally unilateral, paralysis or weakness of
facial musculature consistent with peripheral facial nerve dysfunc-
tion, of no detectable cause (Niparko 1993). Additional symp-
toms frequently include pain around or behind the ear sometimes
extending into the occipital or cervical region. Impaired tolerance
to ordinary levels of noise and disturbed sense of taste on the same
side may also be present (Burgess 1984).
Epidemiological studies have reported an annual incidence of 23
to 25 per 100,000 per year (Martyn 1997; Victor 1994), but one
study using a general practitioner (GP) database has suggested it
may be even higher at 37 per 100,000 per year (Morales 2013).
Bell’s palsy affects men and women more or less equally. Un-
til recently was thought to be most common in the 30- to 45-
year age group (Bateman 1992; Brandenberg 1993; Katusic 1986;
Peitersen 1982; Peitersen 2002; Yanagihara 1988), although the
one more recent primary care database study suggested a peak in
people over 70 years of age (Morales 2013). The condition presents
disproportionately among pregnant women and people who have
diabetes, influenza, a cold, or some other upper respiratory ail-
ment. On average, every year a British GP will see one or two
people who have developed the condition. Both sides of the face
are affected equally often (Prescott 1988).
The aetiology of Bell’s palsy is still debated. A viral infection, vas-
cular ischaemia, autoimmune inflammatory disorders and hered-
ity have been proposed as underlying causes (Adour 1982; Burgess
1984; Lackner 2010). A viral aetiology has gained popularity since
the isolation of herpes simplex virus-1 (HSV-1) genome from the
facial nerve endoneurial fluid of people with Bell’s palsy (Lackner
2010;Murakami 1996). The prognosis is on the whole favourable.
One of the largest series of people with Bell’s palsy including those
who were not receiving specific therapy, showed that 85% of peo-
ple with Bell’s palsy began to recover within three weeks of on-
set (Peitersen 1982). For the remaining 15%, partial recovery oc-
curred three to six months later. The same series showed that nor-
mal facial expression reappeared in 71% of cases, 13% had in-
significant sequelae, and the remaining 16% had permanently di-
minished function with aberrant innervation (expressed as motor
synkinesis or autonomic dysfunction) and post-paralytic spasms.
Description of the intervention
The treatment of Bell’s palsy used to be highly controversial. Cor-
ticosteroids were the treatment of choice, based mainly on non-
randomised comparisons (Adour 1972). The authors of numer-
ous clinical series both espoused and condemned corticosteroid
therapy with, what appeared to them, equally convincing argu-
ments (Burgess 1984). Four systematic reviews found a signifi-
cant trend favouring corticosteroid treatment in improving the re-
covery of facial motor function (de Almeida 2009; Grogan 2001;
Ramsey 2000;Williamson 1996).However, their conclusionswere
affected by including trials of poor quality in the pooled estimate.
de Almeida 2009, a state-of-the-art, high-quality systematic re-
view, differed from our methodology in the way they collected
data, in the inclusion of a non-randomised trial that we excluded
(Martinez 1990), and in the exclusion of a trial that we included
in our analysis (Taverner 1954).
How the intervention might work
Corticosteroids are known to have an anti-inflammatory mode
of action, which reduces oedema and inflammation of the facial
nerve in the acute presentation of Bell’s palsy.
Why it is important to do this review
The purpose of this systematic reviewwas to collect and analyse the
available evidence from randomised controlled trials concerning
the use of corticosteroids for improving the outcome of peoplewith
Bell’s palsy. This is anupdate of a reviewfirst published in 2002 and
last updated in 2010. We updated the review to assess the quality
of the evidence regarding the benefit of corticosteroids in Bell’s
palsy using current methodology, integrate any new evidence and
to determine whether further research would be likely to change
the estimate of effect or its certainty.
O B J E C T I V E S
To determine the effectiveness and safety of corticosteroid therapy
in people with Bell’s palsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials of the use of corticosteroid therapy for the treatment of
recent-onset Bell’s palsy in which an attempt had apparently been
made to conduct a randomised or quasi-randomised comparison
between corticosteroid therapy and a placebo, or open control
group. As in the previous version of the review, we used study
quality as an exclusion criteria excluding trials with a high risk of
bias in several domains.
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Types of participants
Participants of any age with clinically diagnosed Bell’s palsy, irre-
spective of the time of evolution of symptoms.We included all par-
ticipants considered to have Bell’s palsy or acute idiopathic facial
nerve paralysis by the study authors, irrespective of the ancillary
studies they performed to rule out other causes of facial paralysis.
We included in the analysis all participants considered eligible by
the authors of the studies, irrespective of associated conditions.
Types of interventions
We included trials using any corticosteroid or adrenocorti-
cotrophic hormone therapy, irrespective of the route of admin-
istration (oral or parenteral) and length of therapy. We excluded
trials in which a drug considered ’effective’ for this condition was
given to the control group, unless it was given in a similar way to
the experimental group. The exception was studies in which con-
trol and treatment groups received concomitant antiviral therapy;
these are not included in this review, but in the updated Cochrane
review ’Antiviral treatment for Bell’s palsy (idiopathic facial paral-
ysis)’ (Gagyor 2015).
We excluded trials comparing different types of corticosteroids or
different dosage schemes, unless the trial included a placebo group.
Types of outcome measures
Primary outcomes
• Incomplete recovery of facial motor function six months or
more after randomisation.
Secondary outcomes
• Cosmetically disabling persistent sequelae of facial paralysis
(poor recovery of facial motor function as defined by the authors
of the studies) six months or more after randomisation.
• Motor synkinesis or autonomic dysfunction during follow-
up (including facial spasm, motor synkinesis and crocodile tears).
• Adverse effects attributable to the use of corticosteroids.
Search methods for identification of studies
Electronic searches
On4March 2016, we searched theCochraneNeuromuscular Spe-
cialised Register, the Cochrane Central Register of Controlled Tri-
als (CENTRAL in the Cochrane Register of Studies Online), MED-
LINE (January 1966 to February 2016), EMBASE (January 1980
to February 2016) and LILACS (January 1982 to February 2016).
The detailed search strategies are in the appendices: Cochrane
Neuromuscular Specialised Register (Appendix 1), CENTRAL
(Appendix 2), MEDLINE (Appendix 3), EMBASE (Appendix 4)
and LILACS (Appendix 5).
On 21 June 2016, we searched ClinicalTrials.gov and the World
Health Organization International Clinical Trials Registry Plat-
form (ICTRP) (who.int/trialsearch/) for ongoing studies. We
searched both using the term “Bell’s Palsy”.
Searching other resources
We reviewed the bibliographies of the randomised trials and con-
tacted the study authors and known experts in the field to identify
additional published or unpublished data.
Data collection and analysis
Selection of studies
Six review authors scrutinised published and unpublished papers
retrieved by the literature searches to select papers for inclusion.
At least two review authors independently assessed each paper
for relevance, eligibility and quality. There were no disagreements
about inclusion. We applied no language limitations.
Data extraction and management
Review authors collected and analysed data in pairs (FG and VM,
DS and MS, IG and FS). We collected data on the following.
• Methods: study design, study duration, number of study
centres and location, study setting, withdrawals, and date of
study.
• Participants: number (n), mean age, age range, gender,
severity of condition, diagnostic criteria, baseline characteristics,
inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported; definition of recovery status.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
All six review authors had a selection of papers to read, review for
quality and extract data from. At least two review authors assessed
each trial. All review authors agreed data extraction.
Two review authors (IG and VM) inputted data into ReviewMan-
ager 5 (RevMan 2014).
Assessment of risk of bias in included studies
IG completed the ’Risk of bias’ table. FS and FD individually re-
viewed the ’Risk of bias’ assessments. We assessed bias by scoring
studies as at high, low or unclear risk of bias using methods de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011).
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Measures of treatment effect
When comparing studies using different symptom scores to assess
outcomes, we used the House-Brackmann scale when available as
this was the most widely used or had comparisons to other scales
available. When assessing adverse effects, we reported the number
of participants affected, as opposed to the number of events, to
facilitate data comparison.
We used dichotomous outcomes and we analysed data as risk ra-
tios (RR) with a corresponding 95% confidence interval (CI). We
calculated a treatment effect using the Mantel-Haenszel method
(Egger 2007).
Unit of analysis issues
Where a single trial included multiple trial arms, we included only
arms relevant to this review. If two comparisons (e.g. drug A versus
placebo and drug B versus placebo) had been combined in the
same meta-analysis, our preference would be to combine groups
to create a single comparison if appropriate, or otherwise use one
of the other approaches described in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
One of the trial authors, who is also a review author (FS), pro-
vided unpublished trial data. We also contacted a previous study
team member (P Lockhart) for additional information on other
studies and received a response.We either extracted the number of
participants who completed a treatment originally allocated and
the number with the outcome, and considered the potential effect
of missing data when presenting results, or reported intention-to-
treat analyses as presented in trial reports. Where data were un-
available we contacted the original authors, when there was no re-
sponse, we calculated the numbers from the rates and percentages
presented in the papers. We undertook no sensitivity analyses for
missing values. For some trials, we calculated either number in the
analysis or the number experiencing an event using the percentage
experiencing an event.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis, using the thresholds in the Cochrane Handbook
for Systematic Reviews of Interventions as guidance (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We interpreted the I2 statistic in the context of its CI, the Chi2
test, P value and the size of the effect.
Assessment of reporting biases
Since we were unable to pool more than 10 trials, we could not
create a funnel plot to explore possible small-study biases.
Data synthesis
We used a fixed-effect model for our analysis and performed a
sensitivity analysis with a random-effects model.
If the review had included more than one comparison that could
not be included in the same analysis, we would have reported the
results for each comparison separately.
Throughout we have utilised the following notations:
OS: corticosteroid treatment alone
OO: placebo or no treatment only
Using these notations, we conducted the following comparison:
OS versus OO.
’Summary of findings’ table
At this update, we added a ’Summary of findings’ table. We used
the following outcomes: incomplete recovery, cosmetically dis-
abling persistent sequelae six months or more after randomisation,
motor synkinesis and crocodile tears, and adverse effects.
Under the GRADE approach, the levels of quality of evidence are
high, moderate, low or very low. Assessors start at high quality
and may downgrade the evidence for the pre-specified outcomes
depending on five GRADE considerations, which are: study limi-
tations, consistency of effect, imprecision, indirectness and publi-
cation bias. We used methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We used GRADEpro
software (GRADEpro 2008). We have justified all decisions to
downgrade or upgrade the quality of studies using footnotes and
have made comments to aid readers’ understanding of the review
where necessary.
Subgroup analysis and investigation of heterogeneity
We did not undertake any subgroup analyses for this review. The
protocol detailed possible subgroup analyses, although none were
appropriate for the included studies.
Sensitivity analysis
We carried out the following sensitivity analyses.
• Repeated the analyses excluding smaller and underpowered
studies.
• Repeated the analyses excluding studies with short-term
follow-up (less than nine months).
R E S U L T S
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Description of studies
Results of the search
In the updated searches for this review, we found 59 references
in the Cochrane Neuromuscular Specialised Register, 81 in CEN-
TRAL, 818 in MEDLINE, 117 in EMBASE and 15 in LILACS.
There were seven completed randomised controlled trials compar-
ing corticosteroids with no active control when this reviewwas first
written. In subsequent updates, review authors identifiedfive other
potentially relevant trials (Austin 1993; Bento 1991; Engström
2008; Lagalla 2002; Sullivan 2007).
In all, seven trials including 895 evaluable participants met our
inclusion criteria (Austin 1993; Engström 2008; Lagalla 2002;
May 1976; Sullivan 2007; Taverner 1954; Unuvar 1999).
See Figure 1 for a flow chart illustrating the study selection process
for this update.
Figure 1. Study flow diagram illustrating the study selection process for this update.1. The previous version
of this review listed comparisons involving participants treated with antiviral therapy from Sullivan 2007 and
Engström 2008 as two additional separate studies. These two comparisons are not included in this update.
The previous update of this review, Salinas 2010, listed seven ex-
cluded studies (Akpinar 1979; Austin 1993; Bento 1991; Bento
1994; Brown 1982; Martinez 1990; Wolf 1978). We have linked
two references previously listed as separate trials (Bento 1991 and
Bento 1994) under one trial identifier in this update (Bento 1991).
We included Austin 1993, previously excluded because of poten-
tial attrition bias, as current practice is to include all trials eligible
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according to the selection criteria.
Authors of the last version of this review included groups receiving
antiviral therapy and considered the different comparisons from
Engström 2008 and Sullivan 2007 as separate studies (Engström
2008b and Sullivan 2007b).We did not consider the two antiviral-
treated participant groups from those trials in this updated review.
These comparisons are included in the companion Cochrane re-
view, ’Antiviral treatment for Bell’s palsy (idiopathic facial paral-
ysis)’ (Gagyor 2015). In this update, we included only the com-
parisons of corticosteroid versus placebo or corticosteroids versus
no treatment.
Included studies
Summary details of the included trials are given in Characteristics
of included studies.
Austin 1993 recruited 107 participants whose symptoms had oc-
curred within five days of presentation to the study centre. Of
these, 31 participants did not return for initial follow-up. The
76 remaining participants subsequently entered a double-blinded
randomised controlled study allocating them to a corticosteroid
treatment group (prednisone) or a placebo group. The trial authors
gave no details about binding or randomisation. Assessment of
participants occurred within five days of onset and at “regular in-
tervals until they experienced recovery from their acute paralysis”.
Final follow-up was at six months after recovery. The trial authors
stated, “to be included in the analysis, patients must have com-
pleted follow up until their acute recovery occurred.” Investiga-
tors measured disease status using the House-Brackmann grading
system. At first evaluation, participants underwent various tests
including blood tests, an audiogram, a nerve excitability test using
the maximal stimulation technique and, if indicated, electroneu-
rography. Treatment with prednisone was started at 30 mg twice
daily for the first five days followed by a reducing dose stated by
the trial authors.
The study reportedfinal outcomes on53participants at sixmonths
after recovery. The primary outcome was time to recovery, for
which trial authors found no statistically significant difference be-
tween the two groups. Secondary outcomes included facial paral-
ysis grade at onset versus grade at recovery. There was a statisti-
cally significant difference in incomplete recovery rates favouring
the treatment group: 5/23 participants receiving prednisone had
incomplete recovery at six months versus 10/30 participants re-
ceiving placebo (RR 0.65, 95% CI 0.26 to 1.65). Investigators
found no significant difference in persistence of pain during re-
covery, with 3/23 participants in the prednisone group still expe-
riencing pain at six months, compared with 4/30 participants in
the placebo group (RR 0.98, 95% CI 0.24 to 3.95).
Engström 2008 had a factorial design that randomised 829 par-
ticipants into four treatment groups using a two-stage comput-
erised process. The four treatment groups were prednisolone with
placebo, prednisolone with valaciclovir, valaciclovir with placebo,
and double placebo. Treatment started within 72 hours of symp-
tom onset. The trial was double-blind (administrator and partici-
pant) for assessment of recovery status until the end of follow-up.
Participants were assessed at onset, after two weeks (11 to 17 days)
and after 1, 2, 3, 6 and 12months. Trialists measured disease status
using the House-Brackmann grading system and the Sunnybrook
scale, defining complete recovery status as a Sunnybrook score of
100 and a House-Brackmann grade of I. Data analysis included
an assessment of treatment interaction.
The study reported a positive effect on recovery time due to pred-
nisolone (comparing recovery rates at 12 months in the pred-
nisolone group with the placebo group). For this review, we anal-
ysed the corticosteroid-placebo combination (OS) versus the dou-
ble placebo combination (OO) 12 months after the onset of fa-
cial palsy. Using the Sunnybrook definition, 50/210 participants
had an incomplete recovery with prednisolone compared with a
greater proportion (73/206) in the placebo group (RR 0.67, 95%
CI 0.50 to 0.91).
Lagalla 2002 randomised 62 participants within three days of on-
set of Bell’s palsy to high-dose prednisone, 1 g daily for three days,
then 0.5 g daily for three days, administered intravenously, using
saline solution as a placebo. The age range was 15 to 84 years. Ex-
clusion criteria included peptic ulcer disease, pregnancy, severe hy-
pertension, other neurological conditions, diseases of the ear and
previous treatment. As in Taverner 1954, investigators excluded
participants with herpes zoster oticus from the analyses (four of the
participants initially randomised in Lagalla 2002). The investiga-
tors monitored participants for 12 months. They assessed recovery
of facial motor function using the House-Brackmann scale. The
trial authors reported the development of disabling synkinesis at
12-month follow-up.
Lagalla 2002 reported final outcomes on 58 participants at 12
months. In the prednisolone group, 5/30 participants had incom-
plete recovery, compared with 8/28 participants in the placebo
group (RR 0.58, 95% CI 0.22 to 1.57).
May 1976 included 51 participants within two days of Bell’s palsy
onset and reported outcomes using clinical assessment and photo-
graphic documentation without a validated scoring system. The
trial report did not specify the age range of participants in this
double-blinded study. In the intervention group, participants re-
ceived prednisone 410 mg in descending doses over 10 days. The
placebo intervention was vitamins. Trialists excluded people with
chronic otitis media, trauma, loss of lacrimation, or recurrent or
bilateral palsy.
May 1976 was the only study that stated that there was no benefit
from corticosteroids for the recovery of Bell’s palsy (RR 1.16, 95%
CI 0.57 to 2.36).
Sullivan 2007 recruited 551 participants to be treated within 72
hours of onset. Participants were randomised by a dedicated re-
mote telephone-computerised mechanism in a two-stage process
into four treatment groups in a factorial design: prednisolone with
placebo, prednisolonewith aciclovir, aciclovirwith placeboor dou-
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ble placebo. Participants received prednisolone 25 mg twice daily
for 10 days. The trial was blinded for administrator, participant
and assessment of recovery status until the endof follow-up. Assess-
ments took place at onset, after three months and, if participants
were still unwell, again after nine months. The investigators mea-
sured recovery status on the House-Brackmann scale, with com-
plete recovery defined as House-Brackmann grade I. Data analysis
included an assessment of treatment interaction.
Sullivan 2007 reported final outcomes on 496 completed partici-
pants at three and nine months. In the corticosteroid (OS) group,
5/127 participants had incomplete recovery, compared with 18/
122 participants in the placebo (OO) group (RR 0.27, 95% CI
0.10 to 0.70).
Taverner 1954 was a double-blind trial that included 26 partic-
ipants with a range of ages from 12 to 76 years within 10 days
of onset of Bell’s palsy. Participants received either oral cortisone
acetate 1 g in descending doses over eight days or placebo tablets.
Participants weremonitored for up to 157 days. The trial excluded
participants with other neurological conditions or diseases of the
ear. Taverner 1954 included participants with herpes zoster oti-
cus. These participants were allocated in equal numbers to each
treatment arm, and trial authors excluded them from the analyses.
The trialists did not used a validated scoring system to measure
outcomes.
Taverner 1954 used the recovery of facial motor function as the
main outcome measure and reported a small, non-significant ben-
efit of corticosteroids compared with placebo; CIs allowed for ef-
fects in either direction (RR 0.86, 95% CI 0.27 to 2.71).
Unuvar 1999 conducted a non-blinded, randomised controlled
trial on children with severe to complete presentation of Bell’s
palsy (House-Brackmann grades IV to V). They randomised 42
children with an age range of 24 to 74 months using a computer-
generated random sequence into two groups. All participants en-
tered the trial within three days of onset of Bell’s palsy and received
either methylprednisolone 1 mg/kg daily for 10 days then grad-
ually withdrawn over three to five days or no specific treatment.
They excluded participants with other neurological conditions,
diseases of the ear or systemic diseases. The primary outcome was
the recovery of facial motor function measured on the House-
Brackmann facial grading system.
Unuvar 1999 reported a benefit from the treatment with corticos-
teroids although wide CIs allowed for the possibility of both no
effect and a large effect (RR 0.14, 95% CI 0.01 to 2.61).
Ongoing studies
We identified one trial report on the World Health Organization
International Clinical Trials Registry Platform search portal (Babl
2015). From thewebsite, it appeared that the study has now started
recruitment; we will assess this trial fully in future review updates.
See Characteristics of ongoing studies.
Excluded studies
Akpinar 1979 compared three groups of 10 participants each;
two groups received different dosage regimens of corticosteroids,
and the other received placebo. It was unclear who diagnosed
the participants with Bell’s palsy and there were varying dosage
regimens of corticosteroids used. Two studies were not randomised
or quasi-randomised (Brown 1982; Martinez 1990). It was not
possible to extract complete informationon the specified outcomes
for one study (Wolf 1978). Finally, we excluded Bento 1991 as
number of participants and outcome events by treatment groups
was not provided; in addition, 50% of the participants were lost
to follow-up.
Risk of bias in included studies
Figure 2 summarises the ’Risk of bias’ assessment for each included
study.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each methodological quality item for
each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (-) = high risk of bias.
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Allocation
All included trials reported the method of randomisation. Four
used randomisation centralised at a pharmacy, in accordance with
a master sheet of random numbers (May 1976; Taverner 1954),
or an automated permuted block technique (Engström 2008;
Sullivan 2007). One study used a random number list (Lagalla
2002), and another used a computer-based program (Unuvar
1999). It was not clear from the reports if there was adequate al-
location concealment in Lagalla 2002 or Unuvar 1999. We con-
sidered none of the trials to be at high risk of bias for random
sequence generation or allocation concealment.
Blinding
Five trials were double-blind, using placebo in the control
group (Engström 2008; Lagalla 2002; May 1976; Sullivan 2007;
Taverner 1954). Two of these trials used lactose as the placebo
(Sullivan 2007; Taverner 1954), one used vitamins (May 1976),
and one used a saline solution (Lagalla 2002). Two trials did not
specify what was used as placebo, but they stated that this was for-
mulated to have the same size, smell and colour (Engström 2008;
Unuvar 1999). In the trial using vitamins as placebo, the exper-
imental group received similar looking capsules containing pred-
nisone plus vitamins. The trial using saline solution as placebo
gave intramuscular vitamins to all participants for 15 days (Lagalla
2002). In one trial, it was not clear from the report if the physi-
cians administering the drug were blinded (Lagalla 2002). There
were no serious imbalances in baseline prognostic factors between
groups.
Incomplete outcome data
Engström 2008, Sullivan 2007; and Taverner 1954 had drop-out
rates of less than 10%. No participants dropped out in May 1976.
Lagalla 2002 included drop-outs in analyses on an intention-to-
treat basis, by assuming that drop-outs had a poor outcome. Austin
1993 had a drop-out rate of 50% for outcomes six months after
recovery. Unuvar 1999 did not report on attrition.
Selective reporting
All studies reported their intended primary outcomes. Engström
2008 reported all primary outcomes, with secondary outcomes
reported in subsequent publications (Axelsson 2012; Berg 2012).
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Corticosteroids compared to placebo or no treatment for Bell’s
palsy
As all trials reported different intervals and lengths of follow-up,
we performed analyses on data reported at the end of the study
periods. These were 157 days (Taverner 1954), six months (May
1976; Austin 1993), nine months (Sullivan 2007), and 12 months
(Engström 2008; Lagalla 2002; Unuvar 1999).
Primary outcome
Incomplete recovery of facial motor function six months or
more after randomisation
All seven trials, with 895 participants, provided data for the out-
come complete recovery of facial motor function at six months’
follow-up or more (we included data from Taverner 1954, which
reported at five months). The number of people with incomplete
recovery at six months’ follow-up was lower in the corticosteroid
group compared to the control group (RR 0.63, 95% CI 0.50 to
0.80) (Analysis 1.1; Figure 3).
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Figure 3. Forest plot of comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO), outcome:
1.1 Incomplete recovery ≥ 6 months after randomisation.
The tests for statistical heterogeneity were marginally significant
(Chi2 = 7.32, P value = 0.29, I2 = 18%). This small degree of het-
erogeneity was due to the differences in the findings between the
large studies (Engström 2008; Sullivan 2007), and small, under-
powered studies (Austin 1993; Lagalla 2002; May 1976; Taverner
1954; Unuvar 1999). There were better outcomes in two of the
studies (Engström 2008; Sullivan 2007).
The number of people who need to be treated with steroids to
avoid one person with incomplete recovery was 10 (95% CI 6 to
20).
Sensitivity analyses
We removed smaller underpowered studies (Austin 1993; Lagalla
2002; May 1976; Taverner 1954; Unuvar 1999) from the main
analysis leaving the two largest studies (Engström 2008; Sullivan
2007). This analysis confirmed the size and direction of effect, but
with higher statistical heterogeneity (RR 0.59, 95% CI 0.44 to
0.79, Chi2 = 3.32, I2 = 70%).
We analysed the main outcome for the studies that had the longest
follow-up (i.e. between nine and 12 months) (Engström 2008;
Lagalla 2002; Sullivan 2007). This did not significantly change
the result.
Secondary outcomes
Cosmetically disabling persistent sequelae six months or
more after randomisation
Two trials with 75 participants provided data on the number of
participants with severe paralysis, or what may be judged as cos-
metically disabling sequelae, at six months’ follow-up or more
(May 1976; Taverner 1954). When we combined the data, the
number of participants with cosmetically disabling sequelae was
similar in the corticosteroid group and the control group (RR
0.96, 95% CI 0.40 to 2.29) (Analysis 1.2; Figure 4)
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Figure 4. 1.2 Cosmetically disabling persistent sequelae ≥ 6 months after randomisation.
Motor synkinesis or crocodile tears during follow-up
Three trials, with 485 evaluable participants, reported separate
data on motor synkinesis or crocodile tears during follow-up (
Austin 1993; Engström 2008; Lagalla 2002). Two trials reported
the occurrence of disabling synkinesis at 12 months’ follow-up
(Engström 2008; Lagalla 2002); the other trial reported at six
months’ follow-up (Austin 1993). After pooling these data, we
found a significant reduction in the number of people with motor
synkinesis in the corticosteroid group (40/241) compared to the
placebo group (64/248) (RR 0.64, 95%CI 0.45 to 0.91) (Analysis
1.3; Figure 5).We found no statistical heterogeneity (Chi2 = 0.42,
df = 2 (P = 0.81), I2 = 0%).
Figure 5. Forest plot of comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO), outcome:
1.3 Motor synkinesis and crocodile tears.
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Adverse effects attributable to the use of corticosteroids
Three studies explicitly recorded the absence of adverse effects
attributable to the experimental treatment (May 1976; Taverner
1954; Unuvar 1999). One trial reported that three participants
receiving prednisone had temporary sleep disturbances (Lagalla
2002). Another reported “no severe side effects of steroid therapy”,
although there were single reported cases of mood swings, dys-
pepsia andminor conjunctivitis by individual participants (Austin
1993). Two trials gave a detailed account of 93 adverse effects
(Engström 2008; Sullivan 2007), all of them non-serious, with no
significant difference between people receiving corticosteroids and
people receiving placebo (RR 1.04, 95% CI 0.71 to 1.51). Three
deaths occurred; all were deemed to be unrelated to treatment, all
were in the groups not receiving prednisolone. One man with a
history of recurrent atrial fibrillation had a transient relapse while
taking prednisolone and valaciclovir (Figure 6).
Figure 6. Forest plot of comparison: 1 Incomplete recovery of facial motor function, outcome: 1.4 Adverse
effects.
Subgroup analyses
In this updated version of the review, we did not perform any
subgroup analyses.
D I S C U S S I O N
Summary of main results
High-quality evidence from randomised controlled trials indicated
benefit from the use of corticosteroids in Bell’s palsy.
Two trials reached a statistically significant difference favouring the
use of prednisolone (Engström 2008; Sullivan 2007). Meta-analy-
sis of the complete high-quality randomised controlled trial litera-
ture convincingly supported a beneficial effect of prednisolone for
reducing the numbers of participants with incomplete recovery.
Moderate-quality evidence indicated that participants who re-
ceived corticosteroid treatment had less motor synkinesis and
crocodile tears than the placebo group.
Based on these two studies, low-quality evidence revealed no im-
portant differences between corticosteroids and placebo in cos-
metically disabling persistent sequelae, but wide CIs allowed for
the possibility of an effect in either direction.
The included studies did not report differences in the occurrence
of adverse effects between corticosteroids and placebo and addi-
tionally no serious adverse effects were reported. However, cor-
ticosteroids have well-known adverse effects, of which the inci-
dence rises markedly with prolonged dosages above 10mg of pred-
nisolone or its equivalent per day (Dollery 1999). Usually cor-
ticosteroid courses in Bell’s palsy are short and the dose quickly
reduces, making the likelihood of adverse effects in practical use
less than in longer-term indications.
Overall completeness and applicability of
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evidence
No new studies have been published since the previous Cochrane
review (Salinas 2010). The two most recent, well-powered studies
(Engström 2008; Sullivan 2007), with five smaller studies (Austin
1993; Lagalla 2002; May 1976; Taverner 1954; Unuvar 1999),
provided a significant result based on the evidence provided. These
studies sufficiently address the objectives of this review in that they
investigate all relevant participants, interventions and outcomes.
The findings are in accordance with suggested current clinical
practice (Madhok 2009).
Quality of the evidence
For the main outcome of this review (incomplete recovery six
months or more after randomisation), all seven studies combined
provided high-quality evidence. In addition, for motor synkine-
sis and crocodile tears, data from three studies provided moder-
ate-quality evidence. Cosmetically disabling persistent sequelae six
months or more after randomisation was the only analysis per-
formed where the quality of evidence was low. For adverse effects,
the evidence was moderate quality. Reasons for downgrading the
quality of evidence were that in one study participants and asses-
sors were not blinded to the treatment that they received (Unuvar
1999), and in another study, loss to follow-up was 50%, represent-
ing incomplete outcome data (Austin 1993). Two studies excluded
participants who were found after randomisation to have clinical
evidence of herpes zoster infection (Lagalla 2002; Taverner 1954).
Two studies did not use a standardised scale for assessment of facial
motor function (May 1976; Taverner 1954). We considered the
effects of these factors on the quality of the evidence insufficient
for further downgrading for indirectness of evidence. The results
of the majority of studies in this review were consistent with each
other, apart from those of one older, smaller study (May 1976).
Potential biases in the review process
To help ensure that decisions about which studies to include in
this review were reproducible, two review authors repeated the
process (we divided the studies into three groups). There was no
distinction made on the experience and expertise of each author
in the reviewing pairs. On applying the eligibility criteria and
assessing the relevance of studies, review authors were aware of the
names of the study authors, institutions, journal of publication
and results. FS and FD did not assess their own trial (Sullivan
2007). There were no final disagreements about which studies
should be included. According to previous practice in this review,
we excluded several studies and a published abstract that provided
insufficient information. Therefore, there might be some risk of
publication and selective reporting bias due to data from some
studies being unavailable.
Agreements and disagreements with other
studies or reviews
Our results are coincident with three previous systematic reviews,
which found that corticosteroids significantly improved the prog-
nosis of people with Bell’s palsy (de Almeida 2009; Ramsey 2000;
Williamson 1996). All three reviews, even though of good qual-
ity, included a study that lost 50% of participants to follow-up
(Bento 1991). Only one of them, de Almeida 2009, was carried
out after the publication of the largest trials included in our re-
view (Engström 2008; Sullivan 2007). Two of them (de Almeida
2009; Ramsey 2000) also included a non-randomised study in the
analyses (Martinez 1990; Shafshak 1994). A Practice Parameter
published by the American Academy of Neurology concluded that
corticosteroids were safe and probably effective in improving facial
functional outcomes in people with Bell’s palsy (Grogan 2001).
This Practice Parameter was published, also, before the publica-
tion of Sullivan 2007 and Engström 2008.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
According to high-quality evidence, 10 people with Bell’s palsy
need to be treated with corticosteroids to avoid one incomplete
recovery. The available evidence from randomised controlled trials
shows that corticosteroids significantly reduce the frequency of
incomplete recovery from Bell’s palsy.
Implications for research
Further research on Bell’s palsy treatment should consider giving
corticosteroids to those participants acting as controls.
There should be no further studies that do not include corticos-
teroids as a treatment for Bell’s palsy. No participants should be
given placebo or no treatment in any future studies. There is an
adequate body of evidence to support the use of corticosteroids in
the treatment of Bell’s palsy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Austin 1993
Methods Double-blind, randomised, controlled study
Participants 107 people were initially randomised; 76 completed follow-up until acute recovery and
were included in the study analyses
Participants were treated within 5 days of onset
Sex: male 39 (51%), female 37 (49%)
Age: mean 36.8 years, range 18 to 70 years
37 cases (49%) right side palsy and 39 cases (51%) left side palsy
Interventions • Prednisone (n = 35): in a scheduled dosage (30 mg twice daily for 5 days reducing
to 20 mg twice daily on day 6, 15 mg twice daily on day 7, 10 mg twice daily on day 8,
5 mg twice daily on day 9, and 5 mg once daily on day 10)
• Equivalent placebo (n = 31)
Outcomes Primary outcome:
• time to resolution in days of facial function as defined by the House-Brackmann
scale
Secondary outcomes:
• distribution of facial nerve grade at 6 months after recovery, in addition to
• crocodile tears and
• anxiety during follow-up
Follow-up up to 9 months
Funding Not stated
Conflicts of interest Not stated
Date conducted 1 October 1989 to 31 December 1990
Notes Good recovery defined as grade I or II of the House-Brackmann scale
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised at the pharmacy
but details not given
Allocation concealment (selection bias) Unclear risk Allocation of participants not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The study was blinded to both the
patient and the clinical investigators”. Fur-
ther details of blinding not given
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Austin 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The study was blinded to both the
patient and the clinical investigators”. Fur-
ther details of blinding not given
Incomplete outcome data (attrition bias)
All outcomes
High risk 107 participants randomised, 31 did not
attend for follow-up assessment. 76 allo-
cated to prednisone or placebo
Analysis 6 months after resolution of Bell’s
palsy included 53 participants (23 pred-
nisolone and30placebo), representing over
50% loss to follow-up at this point. Rea-
sons for additional drop-outs at 6 months
not described
Selective reporting (reporting bias) Low risk All primary outcomes reported
Other bias Low risk Single-centre study
Engström 2008
Methods Randomised, placebo-controlled trial with 4 treatment groups
Participants 829 participants randomised within 72 hours of facial palsy onset
No contraindications to corticosteroid or antiviral use
Sex: male 341 (41%), female 488 (59%)
Age: mean 40 years, range 31-54 years
Interventions Participants allocated into 1 of 4 treatment groups:
• prednisolone with placebo
• valaciclovir with prednisolone
• valaciclovir with placebo
• double placebo
Dosages: valaciclovir 1000 mg 3 times daily for 7 days; prednisolone 60 mg daily for 5
days
Outcomes Primary outcome:
• recovery of facial function, as assessed at visits with the Sunnybrook scale and the
House-Brackmann scale
Complete recovery was taken as Sunnybrook scale 100 and House-Brackmann scale
grade I
Other outcomes:
• degree of pain, as recorded during the first 2 months
• adverse effects recorded for the first month
• frequency of severe pain, synkinesis, facial spasm and residual facial symptoms at
12 months
Follow-up at 2 weeks, and 1, 2, 3, 6 and 12 months after randomisation, according to
recovery
22Corticosteroids for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Engström 2008 (Continued)
Final outcomes reported at 12 months
Funding Uppsala University; GlaxoSmithKline (Sweden); Pfizer AB (Sweden); Acta Otolaryn-
gologica Foundation; Rosa and Emanuel Nachmanssons Foundation; Stig and Ragna
Gorthon Foundation; Torsten Birger Segerfalk Foundation; Margit Arstrups Founda-
tion; County Council of Ska ne; Helsinki University Central Hospital Research Funds
Conflicts of interest One author was paid by GlaxoSmithKline for a lecture on Bell’s Palsy
Date conducted May 2001 to September 2006
Notes Multicentre
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated by computer number generator.
Sequentially numbered identical contain-
ers allocated to participants on entry into
the trial, by the recruiting physician
Allocation concealment (selection bias) Low risk Allocation sequence double-blind and gen-
erated by a computer number generator in
random permuted blocks of 8
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs issued in identical containers.
All participants blinded to treatment group
until study completion. All study person-
nel and data analysts blinded to treatment
group until study completion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and data analysts
blinded to treatment group until study
completion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers lost to follow-up and reasons
given:
• 213 randomised to corticosteroids: 3
did not receive the drug, 24 lost to follow-
up at 12 months (12.7%); 210 analysed
• 209 randomised to placebo: 3 did
not receive the placebo; 18 lost to follow-
up at 12 months; 206 analysed
’Modified’ intention-to-treat analyses used.
All randomised participants who received
at least 1 dose of study medication in-
cluded, but participants who did not start
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Engström 2008 (Continued)
therapy excluded. Last observation carried
forward method used for the modified in-
tention-to-treat analysis, and missing data
points imputed in the post-baseline follow-
up visits from the last observation available
for each participant
Selective reporting (reporting bias) Low risk All primary outcomes reported. Other out-
comes reported in another paper due to
space constrictions
Other bias Low risk No other biases identified
Lagalla 2002
Methods Randomised, placebo-controlled, double-blind trial
Participants 62 participants within 3 days of onset of onset of Bell’s palsy; 4 people excluded after
randomisation because of acute herpes zoster infection
Sex: male 34, female 28
Age: mean (± SD) 47.5 (± 19) years, range 15 to 84 years
Participants with contraindications to corticosteroids (peptic ulcer disease, pregnancy,
severe hypertension), or previously treated excluded. No losses to follow-up
34 cases left palsy, 28 cases right palsy
Interventions • Prednisone: 1 g daily intravenously in saline solution for 3 days and then 0.5 g for
the other 3 days
• Placebo: saline solution
All participants received intramuscular vitamins for 15 days
Outcomes Primary outcome:
• recovery of facial function
Used House-Brackmann scale for assessment. “Good recovery” was grades I or II
Secondary outcomes:
• motor synkinesis and crocodile tears
Follow-up at 1, 3, 6 and 12 months
Final outcomes reported at 6 and 12 months
Funding Not stated
Conflicts of interest Not stated
Date conducted Not stated
Notes Single centre
Risk of bias
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Lagalla 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random list used to generate random se-
quence
Allocation concealment (selection bias) Unclear risk Not stated by authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded to the treatment.
Saline solution was used as a placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers lost to follow-up and reasons
given: 62 people randomised, 4 excluded
after randomisation (2 in each group) be-
cause of herpes zoster infection; the remain-
ing 58 completed study
Trial authors stated: “Comparative statis-
tics was carried out on an intention-to-
treat basis, by assuming that drop-outs had
a poor outcome. Data analysis concerning
basal features included all patients enrolled.
The analysis of clinical grading changes in-
cluded data from only 58 subjects”
Selective reporting (reporting bias) Low risk Primary and secondary outcomes reported
Other bias Low risk No other bias identified
May 1976
Methods Double-blind, placebo-controlled, randomised trial with 2 treatment groups
Participants 51 participants within 2 days of onset of Bell’s palsy
People with chronic otitis, trauma, loss of lacrimation, and bilateral or recurrent palsy,
and herpes zoster excluded
Sex: male 28, female 23
Age: ranges not clearly stated “30 years or less and 31 years or older”
Interventions • Prednisone: 410 mg in descending doses over 10 days, plus vitamins
• Placebo: vitamins alone
Outcomes Primary outcome:
• complete recovery of facial function
Assessment made clinically using photographs (examples given in the paper) at 6months
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May 1976 (Continued)
after onset
Secondary outcomes:
• pain
• taste
• hyperacusis
• time to recovery
No adverse effects reported
Funding Not stated
Conflicts of interest Not stated
Date conducted 1972 to 1974
Notes Single centre
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random stratified sequence generated by a
statistician, administered in a pharmacy
Allocation concealment (selection bias) Low risk Allocation of treatment group unknown to
both participants and physicians
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. Placebo was similar-look-
ing tablets containing vitamins
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on loss to follow-up rates
Selective reporting (reporting bias) Unclear risk Primary outcomes reported, adverse effects
not reported
Other bias Low risk No other bias identified
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Sullivan 2007
Methods Double-blind, placebo-controlled, randomised, factorial trial
Participants 552 participants randomised and 496 included in final outcome assessment
Referred for assessment and treatment within 72 hours of paralysis onset
All participants aged ≥ 16 years and no contraindications to corticosteroids or antiviral
therapy
Sex: male 253 (51%), female 243 (49%)
Age: mean (± SD) 44 (± 16.4) years
Interventions Participants allocated to 1 of 4 treatment groups to receive:
• aciclovir
• prednisolone
• aciclovir with prednisolone
• placebo
Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg 5
times daily for 10 days, both treatments or neither treatment, depending on allocation
Outcomes Primary outcome:
• recovery rated on House-Brackmann scale, where recovery was grade I
Secondary outcomes:
• health-related quality of life
• Health Utilities Index Mark 3
• facial appearance (Derriford Appearance Scale)
• pain
• adverse effects
• frequency of incomplete recovery at end of study
Follow-up at 3 and 9 months
Final outcomes reported at 9 months
Funding Supported by a grant (02/09/04) from the Health Technology Assessment Programme
of the National Institute for Health Research (Department of Health, England). The
Scottish Executive (Chief Scientist Office and National Health Service Education for
Scotland) funded the Scottish School of Primary Care during the study. Practices were
reimbursed for their contributions through national Support for Science mechanisms
Conflicts of interest Drs Sullivan and Donnan reported receiving grant support from GlaxoSmithKline for
projects unrelated to the trial. No other potential conflict of interest relevant to this
article reported
Date conducted June 2004 to June 2006
Notes Multicentre: 17 hospitals
Risk of bias
Bias Authors’ judgement Support for judgement
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Sullivan 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “... patient was randomly assigned
to a study group by an independent, se-
cure, automated telephone randomisation
service”
Allocation concealment (selection bias) Low risk All parties blinded to allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants not receiving active drug re-
ceived placebo. All administered medica-
tion was identical and in identical contain-
ers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Frequency and reason for drop-outs docu-
mented:
138 assigned toprednisolone, ofwhom127
completed the trial: 3 received an incorrect
drug and 11 were lost to follow-up (4 with-
drew consent, 2 sought active treatment, 1
did not provide primary outcome data, 4
could not be contacted after the 1st visit)
141 assigned to placebo of whom 122 com-
pleted the trial: 19 were lost to follow-up
(6 withdrew consent, 3 could not be con-
tacted, 3 sought active treatment, 1 did not
provide primary outcome data, 3 could not
be contacted after the 1st visit, 2 died, 1
withdrawn by investigator)
Selective reporting (reporting bias) Low risk All planned outcome measures reported
Other bias Low risk Noother potential sources of bias identified
Taverner 1954
Methods Double-blind, randomised controlled trial
Participants 26 participants within 10 days of onset of Bell’s palsy
Sex: male 13 and female 13
Age: range 12 to 76 years
Interventions • Cortisone acetate: orally in descending doses over 8 days (200 mg in divided doses
daily for the first 3 days, 100 mg daily for 3 days and 50 mg daily for 2 days)
• Placebo: same number of lactose tablets for the same period
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Taverner 1954 (Continued)
Outcomes Primary outcomes:
• recovery of facial function (clinical assessment)
• signs of denervation on electromyographic examination
Secondary outcome:
• duration of recovery
Final outcome reported at 157 days
Funding Medical Research Council supplied cortisone acetate
Conflicts of interest Not stated
Date conducted August 1953 to June 1954
Notes Single-centre study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation centralised in pharmacy, in
accordance with a master sheet of random
numbers
Allocation concealment (selection bias) Low risk Central allocation in pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Assessors and participants both blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors and participants both blinded
(the point to which assessors were blinded
was not clear)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 people excluded from analysis because of
herpes of the external meatus
Selective reporting (reporting bias) Unclear risk Adverse effects not reported
Other bias Low risk No other bias identified
Unuvar 1999
Methods Randomised controlled trial
Participants 42 children within 3 days of onset of Bell’s palsy
Sex: male 21, female 21
Age: mean (± SD) 56.9 (± 4.7) months, range 24 to 74 months
Children with chronic neurological conditions, other reasons for facial palsy and acute
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Unuvar 1999 (Continued)
otitis media excluded
Interventions • Oral methylprednisolone: 1 mg/kg daily, for 10 days, and then withdrawn in 3 to
5 days
• Control: no specific treatment (no placebo used)
Outcomes Primary outcome:
• recovery of facial motor function (House-Brackmann scale)
Secondary outcome:
• adverse effects
Follow-up at 4, 6 and 12 months
Funding Not stated
Conflicts of interest Not stated
Date conducted Not stated
Notes Single-centre study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Participants allocated to groups by concealed computer-
generated random sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not blinded to the treatment that they were
receiving
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors not blinded to the treatment that participants
were receiving
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported
Selective reporting (reporting bias) Low risk Outcomes given by authors
Other bias Low risk No other potential biases were identified
n: number of participants; SD: standard deviation.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akpinar 1979 Allocation to treatment group was according to the day of admission, which is a method that is highly susceptible
to bias. It was not clear who diagnosed participants with Bell’s palsy and they used varying dosage regimens of
corticosteroids. Follow-up 3 weeks
Bento 1991 Did not provide the number of participants and outcome events by treatment groups. 50% of participants lost to
follow-up
Brown 1982 Not randomised or quasi-randomised. There was no placebo group or open control group
Martinez 1990 Not randomised or quasi-randomised. 27% of participants lost to follow-up
Wolf 1978 Unable to extract complete information on the specified outcomes
Characteristics of ongoing studies [ordered by study ID]
Babl 2015
Trial name or title Bell’s palsy in children: a multi-centre, double-blind, randomised, placebo-controlled trial to determine
whether prednisolone improves recovery at 1 month
Methods Randomised control trial (computer-generated randomisation schedule), parallel assignment
Participants Participants aged 6 months to 18 years, weight ≥ 5 kg, diagnosed with Bell’s palsy by their treating doctor
and have an acute onset of symptoms of Bell’s palsy for < 72 hours prior to randomisation
Interventions • Prednisolone 1 mg/kg/day (dosing based on weight categories) up to a maximum of 50 mg/day for 10
days
• Placebo: oral liquid with the same ingredients as the intervention solution minus the active drug
Outcomes Primary outcome:
• complete recovery at 1-month post-randomisation, where recovery was defined as a House-Brackmann
facial grading score of I. Recovery assessed by a specialist clinician in a face-to-face setting
Starting date 1 July 2015
Contact information Prof Franz Babl
Emergency Research Department, Murdoch Children’s Research Institute, Royal Children’s Hospital, VIC,
Australia
+61399366748
franz.babl@rch.org.au
Notes www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000563561
31Corticosteroids for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroid (OS) versus placebo or no treatment (OO)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incomplete recovery ≥ 6 months
after randomisation
7 895 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.50, 0.80]
2 Cosmetically disabling persistent
sequelae ≥ 6 months after
randomisation
2 75 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.40, 2.29]
3 Motor synkinesis and crocodile
tears
3 485 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.45, 0.91]
4 Adverse effects 3 715 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.71, 1.51]
Analysis 1.1. Comparison 1 Corticosteroid (OS) versus placebo or no treatment (OO), Outcome 1
Incomplete recovery ≥ 6 months after randomisation.
Review: Corticosteroids for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO)
Outcome: 1 Incomplete recovery ≥ 6 months after randomisation
Study or subgroup OS OO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Austin 1993 5/23 10/30 6.9 % 0.65 [ 0.26, 1.65 ]
Engstro¨m 2008 50/210 73/206 58.7 % 0.67 [ 0.50, 0.91 ]
Lagalla 2002 5/30 8/28 6.6 % 0.58 [ 0.22, 1.57 ]
May 1976 10/25 9/26 7.0 % 1.16 [ 0.57, 2.36 ]
Sullivan 2007 5/127 18/122 14.6 % 0.27 [ 0.10, 0.70 ]
Taverner 1954 4/14 4/12 3.4 % 0.86 [ 0.27, 2.71 ]
Unuvar 1999 0/21 3/21 2.8 % 0.14 [ 0.01, 2.61 ]
Total (95% CI) 450 445 100.0 % 0.63 [ 0.50, 0.80 ]
Total events: 79 (OS), 125 (OO)
Heterogeneity: Chi2 = 7.32, df = 6 (P = 0.29); I2 =18%
Test for overall effect: Z = 3.73 (P = 0.00019)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours OS Favours OO
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Analysis 1.2. Comparison 1 Corticosteroid (OS) versus placebo or no treatment (OO), Outcome 2
Cosmetically disabling persistent sequelae ≥ 6 months after randomisation.
Review: Corticosteroids for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO)
Outcome: 2 Cosmetically disabling persistent sequelae≥ 6 months after randomisation
Study or subgroup OS OO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taverner 1954 3/13 3/11 39.9 % 0.85 [ 0.21, 3.38 ]
May 1976 5/25 5/26 60.1 % 1.04 [ 0.34, 3.16 ]
Total (95% CI) 38 37 100.0 % 0.96 [ 0.40, 2.29 ]
Total events: 8 (OS), 8 (OO)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours OS Favours OO
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Analysis 1.3. Comparison 1 Corticosteroid (OS) versus placebo or no treatment (OO), Outcome 3 Motor
synkinesis and crocodile tears.
Review: Corticosteroids for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO)
Outcome: 3 Motor synkinesis and crocodile tears
Study or subgroup OS OO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Austin 1993 3/23 4/30 5.5 % 0.98 [ 0.24, 3.95 ]
Engstro¨m 2008 32/186 53/188 83.1 % 0.61 [ 0.41, 0.90 ]
Lagalla 2002 5/30 7/28 11.4 % 0.67 [ 0.24, 1.86 ]
Total (95% CI) 239 246 100.0 % 0.64 [ 0.45, 0.91 ]
Total events: 40 (OS), 64 (OO)
Heterogeneity: Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours OS Favours OS
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Analysis 1.4. Comparison 1 Corticosteroid (OS) versus placebo or no treatment (OO), Outcome 4 Adverse
effects.
Review: Corticosteroids for Bell’s palsy (idiopathic facial paralysis)
Comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO)
Outcome: 4 Adverse effects
Study or subgroup OS OO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Engstro¨m 2008 21/203 25/201 54.6 % 0.83 [ 0.48, 1.44 ]
Lagalla 2002 3/32 0/30 1.1 % 6.58 [ 0.35, 122.21 ]
Sullivan 2007 24/127 20/122 44.3 % 1.15 [ 0.67, 1.98 ]
Total (95% CI) 362 353 100.0 % 1.04 [ 0.71, 1.51 ]
Total events: 48 (OS), 45 (OO)
Heterogeneity: Chi2 = 2.31, df = 2 (P = 0.31); I2 =13%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours OS Favours OO
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 MeSH DESCRIPTOR Facial Nerve Diseases [REFERENCE] [STANDARD]
#2 MeSH DESCRIPTOR Bell Palsy [REFERENCE] [STANDARD]
#3 MeSH DESCRIPTOR Facial Paralysis [REFERENCE] [STANDARD]
#4 MeSH DESCRIPTOR Hemifacial Spasm [REFERENCE] [STANDARD]
#5 (((bell* or facial* or hemifacial* or cranial*) NEAR3 (pals* or paralys* or paresi* or spasm*))) AND (INREGISTER) [REFERENCE]
[STANDARD]
#6 #1 or #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR Steroids [REFERENCE] [STANDARD]
#8 steroid or steroids [REFERENCE] [STANDARD]
#9 MeSH DESCRIPTOR Adrenal Cortex Hormones [REFERENCE] [STANDARD]
#10 MeSH DESCRIPTOR Adrenocorticotropic Hormone [REFERENCE] [STANDARD]
#11 MeSH DESCRIPTOR Prednisone [REFERENCE] [STANDARD]
#12 MeSH DESCRIPTOR Prednisolone [REFERENCE] [STANDARD]
#13 MeSH DESCRIPTOR Glucocorticoids [REFERENCE] [STANDARD]
#14 MeSH DESCRIPTOR Cortisone [REFERENCE] [STANDARD]
#15 corticosteroid* or adrenocorticotroph* or prednisone or prednisolone or glucocorticoid* or cortisone or methylprednisone [REF-
ERENCE] [STANDARD]
#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 [REFERENCE] [STANDARD]
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#17 #6 and #16 [REFERENCE] [STANDARD]
Appendix 2. CENTRAL (CRSO) search strategy
Search run on Fri Mar 4 2016
#1 ((Bell or “Bell’s” or Bells or facial or hemifacial or cranial) NEAR (palsy or palsies or paralysis or paresis or spasm or spasms)):
TI,AB,KY 555
#2 (steroid* or corticosteroid* or adrenocorticotroph* or corticotropin or prednisone or prednisolone or glucocorticoid* or cortisone
or methylprednisone or “adrenal cortex hormone*”):TI,AB,KY 37189
#3 (steroid* or corticosteroid* or adrenocorticotroph* or corticotropin or prednisone or prednisolone or glucocorticoid* or cortisone
or methylprednisone or “adrenal cortex hormone*”):TI,AB,KY 37189
#4 #1 AND #2 98
#5 sr-neuromusc:cc 5823
#6 #4 not #5 44
Appendix 3. MEDLINE (OvidSP) strategy
Database: Ovid MEDLINE(R) <1946 to February Week 4 2016>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (407164)
2 controlled clinical trial.pt. (90097)
3 randomized.ab. (304430)
4 placebo.ab. (155333)
5 drug therapy.fs. (1823046)
6 randomly.ab. (215472)
7 trial.ab. (313777)
8 groups.ab. (1364056)
9 or/1-8 (3457470)
10 exp animals/ not humans.sh. (4191570)
11 9 not 10 (2944190)
12 facial nerve diseases/ (1409)
13 Bell Palsy/ (977)
14 Facial Paralysis/ or hemifacial spasm/ (11784)
15 ((bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).tw. (14759)
16 or/12-15 (19812)
17 steroid$.tw. or steroids/ (195309)
18 corticosteroid$.tw. or adrenal cortex hormones/ (111371)
19 adrenocorticotroph$.tw. or corticotropin/ (47991)
20 prednisone.tw. or prednisone/ (46046)
21 prednisolone.tw. or prednisolone/ (38861)
22 glucocorticoid$.tw. or glucocorticoids/ (87141)
23 cortisone.tw. or cortisone/ (22428)
24 methylprednisone.tw. (209)
25 or/17-24 (448308)
26 11 and 16 and 25 (892)
27 remove duplicates from 26 (886)
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Appendix 4. EMBASE (OvidSP) strategy
Database: Embase <1980 to 2016 Week 09>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (46158)
2 double-blind procedure.sh. (126385)
3 single-blind procedure.sh. (21564)
4 randomized controlled trial.sh. (393423)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1223922)
6 trial.ti. (193286)
7 or/1-6 (1370827)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1446761)
9 animal/ or nonanimal/ or animal experiment/ (3498115)
10 9 not 8 (2901774)
11 7 not 10 (1261401)
12 limit 11 to embase (1041826)
13 exp facial nerve paralysis/ (20154)
14 Bell palsy/ (2578)
15 hemifacial spasm/ (2209)
16 ((bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).tw. (18906)
17 or/13-16 (28552)
18 corticosteroid/ or corticosteroid$.tw. (233317)
19 glucocorticoid/ or glucocorticoid$.tw. (101570)
20 corticotropin/ or corticotrophin$.tw. (58083)
21 prednisolone/ or prednisolone.tw. (106302)
22 prednisone/ or prednisone.tw. (142280)
23 or/18-22 (552861)
24 12 and 17 and 23 (133)
25 remove duplicates from 24 (131)
Appendix 5. LILACS IAHx strategy
(“Bell palsy” or “paralisis de Bell” or “paralisia de Bell” or “facial paralysis” or “paralisis facial” or “paralisia facial” or “hemifacial
spasm” or “espasmo hemifacial”) and (MH:D06.472.040$ or steroids or esteroides or cortisone or cortisona or corticoesteroides or
corticosteroides or corticosteroid$or glucocorticoid$or prednisolone or prednisolona or prednisone or prednisona ormethylprednisone)
and ((PT:“Randomized Controlled Trial” or “Randomized Controlled trial” or “Ensayo Clínico Controlado Aleatorio” or “Ensaio
Clínico Controlado Aleatório” or PT:“Controlled Clinical Trial” or “Ensayo Clínico Controlado” or “Ensaio Clínico Controlado” or
“Random allocation” or “Distribución Aleatoria” or “Distribuição Aleatória” or randon$ or Randomized or randomly or “double blind”
or “duplo-cego” or “duplo-cego” or “single blind” or “simples-cego” or “simples cego” or placebo$ or trial or groups) AND NOT
(B01.050$ AND NOT (humans or humanos or humanos)))
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Appendix 6. Clinical trials registries search strategies
ClinicalTrials.gov and World Health Organization International Clinical trials Registry
Bell’s palsy
WH A T ’ S N E W
Last assessed as up-to-date: 4 March 2016.
Date Event Description
4 July 2016 New citation required but conclusions have not changed New author team. One new trial was found, with no
change to previous conclusions. We made the following
corrections and revisions:
• more detailed documentation of methods and
additional sections to comply with current standards
• amendments and corrections in the results section
• inclusion of additional study data in our primary
analysis, which changed the RR for incomplete recovery
from 0.71 (95% CI 0.61 to 0.83) to 0.63 (95% CI 0.50
to 0.80)
• we largely presented available data analyses,
reporting intention-to-treat data only when trialists
used this approach
• removal of comparisons involving antiviral co-
medication, which are analysed in a separate Cochrane
review
• inclusion of an analysis of adverse events
• inclusion of a ’Summary of findings’ table and of
comments on the quality of evidence in the text of the
review
4 March 2016 New search has been performed Searches updated and integrated
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2002
Date Event Description
25 February 2009 New citation required and conclusions have changed New trials have been added leading to a substantial
change in the conclusion of the review
16 July 2008 Amended Converted to new review format.
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(Continued)
23 June 2008 New citation required and conclusions have changed Substantive amendment
28 February 2006 New search has been performed February 2006
We updated the search of the Cochrane Neuromuscu-
lar Disease Group specialised register (November 2005)
, MEDLINE (January 1966 to November 2005), EM-
BASE (January 1980 to November 2005) and LILACS
(January 1982 toNovember 2005).Nonew randomised
controlled trials were found
C O N T R I B U T I O N S O F A U T H O R S
All six review authors worked in pairs on study selection and data extraction.
IG and VM agreed data input into Review Manager 5.
IG performed risk of bias assessments; FS and FD reviewed them.
IG and VM drafted the revised review.
FD assisted with calculations.
VM and IG revised the review after editorial review.
All authors approved the final draft.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• New source of support, Other.
External sources
• No sources of support supplied
39Corticosteroids for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A new author team updated this review: Vishnu B Madhok, Ildiko Gagyor, Fergus Daly, Dhruvashree Somasundara, Michael Sullivan,
Fiona Gammie, Frank Sullivan.
The review authors added a ’Summary of findings’ table and added some sections to the Methods to comply with current Cochrane
standards.
Changes from the previous update of this review
When looking at Engström 2008 and Sullivan 2007, we excluded participants that were given antiviral therapy with corticosteroids or
antiviral therapy alone as these are reported in a separate review (Gagyor 2015).
As a result, in this update we deleted the comparisons from those trials that the previous review authors designated Sullivan b and
Engström b.
We assume that the total number of events given in Engström a (i.e. 213) was incorrect, and changed the figure to 210.
In the previous Cochrane review, authors used intention-to-treat numbers. We decided to perform available-case analysis unless the
trialists reported intention-to-treat data.
We deleted Sullivan b from Table 1.2 “cosmetically disabling persistent sequelae” for the reasons above. Sullivan a did not contribute
data to this table.
In Analysis 1.3, “motor synkinesis of or autonomic dysfunction during follow up”, we deleted Engström b for the reasons above.
In Analysis 1.3, we changed the data for Engström a - the previous Cochrane review correctly gave the number of participants reporting
synkinesis at 12 months in the OS group as 32. We continued to use this event rate, but changed the total sample number from 290
to 186 in accordance with the information given.
We deleted what was previously Analysis 1.4 “incomplete recovery of patients with Bell’s Palsy” as the numbers of participants was
negligible (only 22 participants from two studies Sullivan a and May 1976), after we removed the data from Sullivan b.
We checked the numbers for May 1976; Taverner 1954; and Unuvar 1999. We found that the numbers included for Taverner were
incorrect and updated these in Analysis 1.1.
The previous Cochrane review excluded Lagalla 2002 from the main meta-analysis giving the reason that the paper did not provide
primary outcome data on complete recovery. We decided to include this study given that we could use information on page 109 (results
section) of the paper to calculate the data for input into Analysis 1.1. In the prednisolone group, 32 participants, 83%, had complete
recovery, hence 17% (five participants) had incomplete recovery. In the placebo group, there were 30 participants, of whom 25% (eight
participants) had incomplete recovery.
Based on our changes to Analysis 1.1, the RR changed from 0.51 (95% CI 0.32 to 0.80) to 0.65 (95% CI 0.50 to 0.83).
We added a table of adverse effects (Analysis 1.4).
We checked the data for each of the included studies and made significant amendments and corrections in the Effects of interventions
section.
In the Objectives, we deleted the reference to ’early’ use of corticosteroids in Bell’s palsy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents [∗therapeutic use]; Bell Palsy [∗drug therapy]; Cortisone [∗analogs & derivatives; therapeutic use]; Gluco-
corticoids [adverse effects; ∗therapeutic use]; Methylprednisolone [therapeutic use]; Prednisolone [therapeutic use]; Prednisone [ther-
apeutic use]; Randomized Controlled Trials as Topic; Recovery of Function; Vitamins [therapeutic use]
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MeSH check words
Humans
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